Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.

Chen Z, Gaudino G, Pass HI, Carbone M, Yang H.

Transl Lung Cancer Res. 2017 Jun;6(3):259-269. doi: 10.21037/tlcr.2017.05.06. Review.

2.

Methotrexate and gemcitabine combination chemotherapy for the treatment of malignant pleural mesothelioma.

Kuribayashi K, Miyata S, Fukuoka K, Murakami A, Yamada S, Tamura K, Hirayama N, Terada T, Tabata C, Fujimori Y, Nakano T.

Mol Clin Oncol. 2013 Jul;1(4):639-642. Epub 2013 May 10.

3.

Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma.

Cioce M, Ganci F, Canu V, Sacconi A, Mori F, Canino C, Korita E, Casini B, Alessandrini G, Cambria A, Carosi MA, Blandino R, Panebianco V, Facciolo F, Visca P, Volinia S, Muti P, Strano S, Croce CM, Pass HI, Blandino G.

Oncogene. 2014 Nov 13;33(46):5319-31. doi: 10.1038/onc.2013.476. Epub 2013 Nov 18.

4.

Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo.

Manente AG, Valenti D, Pinton G, Jithesh PV, Daga A, Rossi L, Gray SG, O'Byrne KJ, Fennell DA, Vacca RA, Nilsson S, Mutti L, Moro L.

Oncogenesis. 2013 Sep 23;2:e72. doi: 10.1038/oncsis.2013.32.

5.

Spontaneous mesotheliomas in F344/N rats are characterized by dysregulation of cellular growth and immune function pathways.

Blackshear PE, Pandiri AR, Ton TV, Clayton NP, Shockley KR, Peddada SD, Gerrish KE, Sills RC, Hoenerhoff MJ.

Toxicol Pathol. 2014 Jul;42(5):863-76. doi: 10.1177/0192623313501894. Epub 2013 Aug 26.

6.

miR-1 induces growth arrest and apoptosis in malignant mesothelioma.

Xu Y, Zheng M, Merritt RE, Shrager JB, Wakelee HA, Kratzke RA, Hoang CD.

Chest. 2013 Nov;144(5):1632-1643. doi: 10.1378/chest.12-2770.

7.

Novel therapies in phase II and III trials for malignant pleural mesothelioma.

Zauderer MG, Krug LM.

J Natl Compr Canc Netw. 2012 Jan;10(1):42-7. Review.

8.

Ranpirnase Interferes with NF-κB Pathway and MMP9 Activity, Inhibiting Malignant Mesothelioma Cell Invasiveness and Xenograft Growth.

Nasu M, Carbone M, Gaudino G, Ly BH, Bertino P, Shimizu D, Morris P, Pass HI, Yang H.

Genes Cancer. 2011 May;2(5):576-84. doi: 10.1177/1947601911412375.

9.

Onconase mediated NFKβ downregulation in malignant pleural mesothelioma.

Goparaju CM, Blasberg JD, Volinia S, Palatini J, Ivanov S, Donington JS, Croce C, Carbone M, Yang H, Pass HI.

Oncogene. 2011 Jun 16;30(24):2767-77. doi: 10.1038/onc.2010.643. Epub 2011 Feb 14.

10.

Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma.

Silberhumer GR, Brader P, Wong J, Serganova IS, Gönen M, Gonzalez SJ, Blasberg R, Zamarin D, Fong Y.

Mol Cancer Ther. 2010 Oct;9(10):2761-9. doi: 10.1158/1535-7163.MCT-10-0090. Epub 2010 Sep 21.

11.

hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma.

Pass HI, Goparaju C, Ivanov S, Donington J, Carbone M, Hoshen M, Cohen D, Chajut A, Rosenwald S, Dan H, Benjamin S, Aharonov R.

Cancer Res. 2010 Mar 1;70(5):1916-24. doi: 10.1158/0008-5472.CAN-09-3993. Epub 2010 Feb 16.

12.

Mesothelioma epidemiology, carcinogenesis, and pathogenesis.

Yang H, Testa JR, Carbone M.

Curr Treat Options Oncol. 2008 Jun;9(2-3):147-57. doi: 10.1007/s11864-008-0067-z. Epub 2008 Aug 15. Review.

Supplemental Content

Support Center